T Cell Receptor Therapies Articles & Analysis: This-Year
4 articles found
By administering recombinant chemokines, scientists can redirect immune cells to the tumor microenvironment, potentially enhancing the efficacy of checkpoint inhibitors or CAR-T cell therapies. For instance, CXCL10 has shown promise in preclinical models by enhancing T-cell infiltration into ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...
Among the various forms of immunotherapy, CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) has shown promise, particularly in treating acute lymphoblastic leukemia (ALL), especially in children and young adults. This therapy involves genetically ...